Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study.

Kristen Hansen Steve R Makkar David K Sahner Joshua P Fessel Nathan A Hotaling Hythem Sidky

Published in: medRxiv : the preprint server for health sciences (2023)

In Paxlovid-eligible patients, treatment was associated with decreased risk of hospitalization and death. Results align with prior randomized trials and observational studies, thus supporting the real-world effectiveness of Paxlovid.

Keyphrases

randomized controlled trial
end stage renal disease
systematic review
ejection fraction
newly diagnosed
chronic kidney disease
study protocol
clinical trial
phase iii
patient reported outcomes
patient reported
combination therapy